Dewpoint and Chemify partner for cancer drug discovery
13 Sep 2023
License out/in
Preview
Source: Pharmaceutical Technology
Chemify will carry out the design and delivery of new compounds to boost the oncology and neurodegeneration pipeline of Dewpoint. Credit: metamorworks/Shutterstock.com.
Dewpoint Therapeutics has entered a collaboration with Chemify to expedite the discovery of molecules that target cancer and neurodegeneration.
The companies will leverage the programmable chemistry platform of Chemify to develop an array of digitally discovered and automatically synthesised new molecules against specific condensate targets in the oncology and neurodegeneration pipeline of Dewpoint.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Trastuzumab Rezetecan in Endometrial Cancer GlobalData
Preview
Source: Pharmaceutical Technology
ReportsEsophageal Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape GlobalData
View allCompanies IntelligenceDewpointDewpoint Therapeutics IncChemify LtdView all
The collaboration will combine Chemify’s chemistry artificial intelligence (AI) and automation technology platform with the condensate biology and AI technology platform of Dewpoint.
Chemify’s platform can design, discover and generate complex molecules leveraging a chemical programming language.
Furthermore, the company’s newly developed automated design, discovery and synthesis platform will be used to expedite the efforts of Dewpoint.
Under the deal, Chemify will carry out the design and delivery of new compounds to boost Dewpoint’s pipeline.
Dewpoint also holds an option to purchase the Chemify-designed compounds for which the former will make clinical and regulatory milestones, as well as tiered royalty payments.
Dewpoint Therapeutics CEO Ameet Nathwani said: “Dewpoint’s partnership with Chemify offers an innovative pathway to take our novel chemical matter already in optimisation and bootstrap Chemify’s novel chemical space exploration tool suite using state-of-the-art digital chemistry AI-powered concepts.
“This is a new frontier for drug discovery and we are delighted to partner with Chemify, who is at the cutting edge of this approach.”
Dewpoint applies its knowledge in biomolecular condensates to drug discovery for various ailments or ones that result from condensate dysfunction.
The company has programmes across a pipeline spread over oncology, neurodegenerative, cardiopulmonary and metabolic diseases fields.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.